Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was Well-Tolerated With No New Safety Signals Observed; Results Support The Further Development And Advancement Into A Phase 3 Program
Portfolio Pulse from Benzinga Newsdesk
Sanofi's Phase 2 study results for Rilzabrutinib show potential as the first advanced oral treatment for moderate-to-severe asthma. The data indicates a reduction in loss of asthma control events, improvement in symptoms, and good tolerance with no new safety signals. These results support further development into a Phase 3 program.
May 22, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's Rilzabrutinib shows promising Phase 2 results for moderate-to-severe asthma, supporting further development into Phase 3. The drug demonstrated a reduction in loss of asthma control events, improvement in symptoms, and was well-tolerated with no new safety signals.
The positive Phase 2 results for Rilzabrutinib indicate potential for a new advanced oral treatment for moderate-to-severe asthma, which could significantly impact Sanofi's market position and revenue. The advancement to Phase 3 suggests confidence in the drug's efficacy and safety.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100